A p53-stabilizing agent, CP-31398, induces p21 expression with increased G2/M phase through the YY1 transcription factor in esophageal carcinoma defective of the p53 pathway.
CP-31398
G2/M arrest
YY1
esophageal carcinoma
p21
p53
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
12
2018
accepted:
20
12
2018
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
14
2
2019
Statut:
epublish
Résumé
Restoration of p53 functions is one of the therapeutic strategies for esophageal carcinoma which is often defective of the p53 pathway. We examined effects of CP-31398 which potentially increased expression of wild-type p53 or converted mutated p53 to the wild-type. We used 9 kinds of human squamous esophageal carcinoma cells with different
Types de publication
Journal Article
Langues
eng
Pagination
79-93Déclaration de conflit d'intérêts
None.
Références
Science. 1999 Dec 24;286(5449):2507-10
pubmed: 10617466
Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55
pubmed: 12174820
Mol Cell Biol. 2003 Mar;23(6):2171-81
pubmed: 12612087
Cancer Sci. 2003 Jul;94(7):628-32
pubmed: 12841873
Oncogene. 2003 Nov 13;22(51):8233-45
pubmed: 14614447
J Biol Chem. 2004 Jun 11;279(24):25927-34
pubmed: 15087442
Mol Biol Cell. 2004 Sep;15(9):3965-76
pubmed: 15181148
Cell. 2004 Jun 25;117(7):859-72
pubmed: 15210108
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12165-70
pubmed: 15295102
J Biol Chem. 2004 Oct 29;279(44):45887-96
pubmed: 15308639
J Negat Results Biomed. 2004 Nov 17;3:5
pubmed: 15548325
Br J Dermatol. 2005 Nov;153(5):900-10
pubmed: 16225598
Cancer Sci. 2006 Mar;97(3):183-91
pubmed: 16542214
Clin Cancer Res. 2007 Jun 1;13(11):3380-7
pubmed: 17545546
Circ Res. 2007 Jul 20;101(2):146-55
pubmed: 17556661
Cancer Res. 2008 Mar 15;68(6):1797-808
pubmed: 18339860
Clin Cancer Res. 2008 Oct 15;14(20):6376-86
pubmed: 18927276
Mol Biol Cell. 2009 Apr;20(7):1891-902
pubmed: 19211842
Cell Cycle. 2009 May 1;8(9):1367-72
pubmed: 19342874
Cancer Gene Ther. 2009 Nov;16(11):832-40
pubmed: 19363469
EMBO J. 2010 Sep 1;29(17):2994-3006
pubmed: 20657550
Transcription. 2010 Sep-Oct;1(2):81-4
pubmed: 21326896
Clin Cancer Res. 2011 May 1;17(9):2830-41
pubmed: 21415220
Crit Rev Oncog. 2011;16(3-4):163-97
pubmed: 22248053
Int J Oncol. 2012 May;40(5):1575-80
pubmed: 22322893
Curr Drug Targets. 2014 Jan;15(1):80-9
pubmed: 24387333
Nat Genet. 2014 Aug;46(8):837-843
pubmed: 24952744
Nat Genet. 2014 Oct;46(10):1097-102
pubmed: 25151357
Onco Targets Ther. 2014 Sep 26;7:1753-9
pubmed: 25328408
Nat Commun. 2016 Feb 02;7:10438
pubmed: 26832959
Gastroenterology. 2016 May;150(5):1171-1182
pubmed: 26873401
Pathol Oncol Res. 2018 Jan;24(1):75-81
pubmed: 28341911
Oncotarget. 2017 May 19;8(33):54694-54707
pubmed: 28903375